Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | NK-CAR immunotherapy development over the past 12 months

Evelyn Ullrich • 1 Sep 2020
EBMT 2020
General CAR-T NK-Cell Therapy

Evelyn Ullrich, MD, PhD, Goethe University Frankfurt, Frankfurt, Germany, talks on the development of NK-CAR immunotherapy over the past 12 months and important routes for further study. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Evelyn Ullrich

2:08
Advances in gene engineering technologies for NK cell-based immunotherapy
Evelyn Ullrich • 24 Apr 2023
2:17
Immunity of patients with multiple myeloma after vaccination against COVID-19
Evelyn Ullrich • 5 Dec 2022
3:09
Using CRISPR/Cas9 gene editing to generate NKG2A-knockout CD33-CAR-NK cells for the treatment of AML
Evelyn Ullrich • 5 Dec 2022
4:20
An insight into the use of CAR-NKs for the treatment of AML
Evelyn Ullrich • 15 Mar 2022

Related Videos

1:12
The contribution of viral infections, such as EBV, to post-transplant lymphoproliferative disease
Susan Prockop • 16 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals